WO2002009649A8 - Cell internalized peptide-drug conjugates - Google Patents

Cell internalized peptide-drug conjugates

Info

Publication number
WO2002009649A8
WO2002009649A8 PCT/US2001/024088 US0124088W WO0209649A8 WO 2002009649 A8 WO2002009649 A8 WO 2002009649A8 US 0124088 W US0124088 W US 0124088W WO 0209649 A8 WO0209649 A8 WO 0209649A8
Authority
WO
WIPO (PCT)
Prior art keywords
drug conjugates
lfa
icam
leukocytes
side effects
Prior art date
Application number
PCT/US2001/024088
Other languages
French (fr)
Other versions
WO2002009649A3 (en
WO2002009649A2 (en
Inventor
Teruna J Siahaan
Helena Yusuf-Makagiansar
Meagan Anderson
Rong Christine Xu
Original Assignee
Univ Kansas
Teruna J Siahaan
Helena Yusuf-Makagiansar
Meagan Anderson
Rong Christine Xu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kansas, Teruna J Siahaan, Helena Yusuf-Makagiansar, Meagan Anderson, Rong Christine Xu filed Critical Univ Kansas
Priority to CA002417885A priority Critical patent/CA2417885A1/en
Priority to EP01956077A priority patent/EP1311280A4/en
Priority to JP2002515204A priority patent/JP2004505029A/en
Priority to AU2001278113A priority patent/AU2001278113A1/en
Publication of WO2002009649A2 publication Critical patent/WO2002009649A2/en
Publication of WO2002009649A3 publication Critical patent/WO2002009649A3/en
Publication of WO2002009649A8 publication Critical patent/WO2002009649A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Peptides which bind to leukocytes are conjugated with drugs. Advantageously, the peptide-drug conjugates interfere with ICAM-1/LFA-1 interactions and are internalized by leukocytes, whereby the drug portion of the conjugate exerts potent toxic side effects against targeted cells with minimal adverse side effects. Preferred conjugates include 4-30 mer peptides derived from ICAM-1 or LFA-1 coupled with drugs effective against leukocyte-related diseases.
PCT/US2001/024088 2000-08-01 2001-08-01 Cell internalized peptide-drug conjugates WO2002009649A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002417885A CA2417885A1 (en) 2000-08-01 2001-08-01 Cell internalized peptide-drug conjugates
EP01956077A EP1311280A4 (en) 2000-08-01 2001-08-01 Cell internalized peptide-drug conjugates
JP2002515204A JP2004505029A (en) 2000-08-01 2001-08-01 Peptide-drug conjugate incorporated into cells
AU2001278113A AU2001278113A1 (en) 2000-08-01 2001-08-01 Cell internalized peptide-drug conjugates

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62971900A 2000-08-01 2000-08-01
US09/629,719 2000-08-01

Publications (3)

Publication Number Publication Date
WO2002009649A2 WO2002009649A2 (en) 2002-02-07
WO2002009649A3 WO2002009649A3 (en) 2002-04-11
WO2002009649A8 true WO2002009649A8 (en) 2002-08-01

Family

ID=24524196

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/024088 WO2002009649A2 (en) 2000-08-01 2001-08-01 Cell internalized peptide-drug conjugates

Country Status (5)

Country Link
EP (1) EP1311280A4 (en)
JP (1) JP2004505029A (en)
AU (1) AU2001278113A1 (en)
CA (1) CA2417885A1 (en)
WO (1) WO2002009649A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006227133A1 (en) * 2005-03-22 2006-09-28 Georgetown University Delivery systems and methods for diagnosing and treating cardiovascular diseases
WO2012105813A2 (en) * 2011-02-02 2012-08-09 Medipost Co., Ltd. Use of icam-1 for prevention or treatment of neurological diseases
WO2018031947A1 (en) 2016-08-12 2018-02-15 Immunowork, Llc Diagnosis, prevention, and/or treatment of autoimmune diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5183805A (en) * 1990-08-13 1993-02-02 Board Of Regents, The University Of Texas System Bioactive egf peptides for promotion of tissue regeneration and cancer therapy
EP0762886A4 (en) * 1994-04-19 1999-03-31 Univ Kansas Icam-1/lfa-1 short-chain peptides and method of using same
WO1997041149A1 (en) * 1996-04-26 1997-11-06 The University Of Kansas Peptide compositions which induce immune tolerance and methods of use

Also Published As

Publication number Publication date
WO2002009649A3 (en) 2002-04-11
EP1311280A4 (en) 2005-02-23
JP2004505029A (en) 2004-02-19
CA2417885A1 (en) 2002-02-07
EP1311280A2 (en) 2003-05-21
WO2002009649A2 (en) 2002-02-07
AU2001278113A1 (en) 2002-02-13

Similar Documents

Publication Publication Date Title
NL300903I2 (en) Inotuzumab ozogamicin
EP1374908A3 (en) Polymer-drug conjugates comprising hydrazide linkers
ATE347378T1 (en) CONJUGATES FOR THE TREATMENT OF INFLAMMATORY DISEASES AND ASSOCIATED TISSUE DAMAGE
CY1117729T1 (en) METHODS FOR PREPARATION OF CYTOTOTOXIC CONCENTRATES OF MITSINSINOIDS AND CELL BATTERY AGENTS
IL135148A0 (en) A polysaccharide conjugate and pharmaceutical compositions containing the same
WO2006089156A3 (en) Drug-polymer conjugates coupled to a peptidic carrier
WO2005081711A3 (en) Monomethylvaline compounds capable of conjugation to ligands
WO2004069159A3 (en) Vitamin receptor binding drug delivery conjugates
CA2118032A1 (en) Therapeutic conjugates of toxins and drugs
EP1724353A3 (en) Methods of forming protein-linked lipidic microparticles
WO2002043771A3 (en) Conjugates of glycosylated/galactosylated peptide
WO2005053749A3 (en) Thiol-cleavable linkage between polymer and ligand
WO2005014024A3 (en) Conjugates of a polymer and a protein linked by an oxime linking group
NO963283D0 (en) Non-viral vector
WO2002091989A3 (en) Antiviral therapies using polyamine or polyamine analog-amino acid conjugates
WO2005037992A3 (en) Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
WO2005082023A3 (en) Heterocyclic self-immolative linkers and conjugates
WO2008077956A3 (en) Oligonucleotide-, protein and/or peptide-polymer conjugates
WO2009059309A3 (en) Furin-cleavable peptide linkers for drug-ligand conjugates
WO2003045319A3 (en) Targeted therapeutics and uses thereof
WO2004108747A3 (en) Lectin conjugates
WO2003035011A3 (en) Multidrug multiligand conjugates for targeted drug delivery
WO2005002516A3 (en) Leukocyte internalized peptide-drug conjugates
WO2003094842A3 (en) Conjugates comprising central nervous system active drug
WO2002009649A3 (en) Cell internalized peptide-drug conjugates

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WR Later publication of a revised version of an international search report
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2417885

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002515204

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001278113

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001956077

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001956077

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001956077

Country of ref document: EP